CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
-
D4vd used Amazon chainsaws to hack up teen's body: prosecutors
-
Meta chief Zuckerberg doubles down on AI spending
-
Saudi to end LIV Golf funding this year: reports
-
Google-parent Alphabet soars as Meta stumbles over AI costs
-
Powell's decision to stay on at Fed ignites new Trump insult
-
Brazil lowers benchmark rate to 14.5% in second consecutive cut
-
'This cannot happen': Arsenal's Arteta livid over Eze penalty review
-
Air quality improving in Europe but more effort needed: report
-
Putin, Trump discuss Iran, Ukraine in phone call: Kremlin
-
Crazy flights: Kiss frontman produces plane disaster movie
-
Google-parent Alphabet soars as rivals stumble over AI costs
-
Romanian behind 'swatting' attacks in US gets four years in prison
-
Arsenal, Atletico trade penalties in Champions League semi-final draw
-
Anti-Bezos campaign urges Met Gala boycott in New York
-
African oil producers defend need to drill at fossil fuel exit talks
-
Iran officials leave Canada before FIFA Congress over airport 'insult': Iranian media
-
Oil spikes while divided Federal Reserve keeps interest rates unchanged
-
Palace boss Glasner eager for another trophy in Europe
-
Alleged Trump assassin took selfie moments before attack: prosecutors
-
Shomrim: the Jewish volunteers protecting their community
-
Powell to bow out as Fed chief but stay as a governor on legal pressure
-
PSG blow as Hakimi ruled out of Champions League semi-final return
-
'Gritty' Philadelphia pitches itself as low-cost US World Cup choice
-
'I literally was a fool': Musk grilled in OpenAI trial
-
OpenAI facing 'waves' of US lawsuits over Canada mass shooting
-
Trump says US has 'a shot' at crewed Moon landing before presidency ends
-
Hungary's Magyar pushes to unblock EU billions in Brussels
-
London police probe 'terror' incident after two Jewish men stabbed
-
Rob Reiner autopsy report not ready, court hears
-
Rickelton ton in vain as Hyderabad chase down 244 to beat Mumbai
-
US Fed divided at Powell's likely last meeting at helm
-
Draper out of French Open in fresh injury blow
-
King Charles touts 'solidarity' with US at 9/11 memorial
-
Ticket price hikes not affecting summer air travel demand: IATA
-
Liverpool 'expect Salah to be available' before Anfield exit
-
World snooker champion Zhao Xintong succumbs to 'Crucible curse'
-
Australia FM says China agrees to collaborate on jet fuel exports
-
Pentagon chief spars with Democratic lawmakers on Iran war
-
Hungary's Magyar pushes to unblock EU billion in Brussels
-
Departing US still owes money, says WHO chief
-
Joshua warm-up defeat would 'kill' Fury fight, warns promoter Warren
-
Sinner stops Jodar to book spot in Madrid Open semis
-
Pogacar wins opening full stage to take Tour de Romandie lead
-
'River on fire': Toxic fumes as Ukrainian drones pound Russian oil town
-
Pereira aiming to bring European glory back to Forest
-
Uber adds hotel booking in push to become 'everything app'
-
Oil spikes while stocks slip ahead of US Fed rate decision
-
Two Jewish men stabbed in 'terrorist' attack in London
-
End of an era: last hereditary peers exit UK parliament
-
Canada holds key rate steady, says will act if war inflation persists
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 at 10:00 AM ET.
CASI will also host one-on-one meetings with investors at the conference.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.
CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1/2 study in renal allograft antibody-mediated rejection (AMR) with plans for first patient in Q1 2026.
More information on CASI is available at www.casipharmaceuticals.com.
COMPANY CONTACT:
Ingrid Choong, PhD
650-619-6115
[email protected]
SOURCE: CASI Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
R.Garcia--AT